WHAT DOES IT MEAN TO BECOME PREGNANT WITH JUVENILE IDIOPATHIC ARTHRITIS? A MONOCENTRIC EXPERIENCE IN A TERTIARY CENTRE OF MILAN DEDICATED TO YOUNG ADULTS AFFECTED BY JIA

Irene Pontikaki1, Maria Gerosa2, Lorenza Maria Argolini3, Carolina Artusi3, Alice Grossi3, Paolo Picco1, Stefano Volpi2, Alice Grassi2

1ASST Pini–CTO, Unit Of Pediatric Rheumatology, Milan, Italy
2University of Milan, Chair of Rheumatology, Milan, Italy
3ASST Pini–CTO, Unit Of Rheumatology, Milan, Italy

Background: During the last seventeen years, biological and non-biological therapies have been used in our center in an open prospective study for the treatment of refractory JIA not only in paediatric age but also in young adults. The availability of more effective drugs for JIA has dramatically increased the number of patients willing to become pregnant. Data regarding the effect of JIA on pregnancy outcome are scant.

Objectives: The study aims to evaluate the capability of JIA patients to become pregnant, the effects of drugs on pregnancy outcome and the impact of gestation on the disease course.

Methods: JIA patients regularly followed up in our Transition Clinic of the Division of Rheumatology, Gaetano Pini Institute of Milan, were enrolled in the study at positive pregnancy test. During the whole pregnancy patients underwent monthly clinical examination and obstetric ultrasound. Data regarding disease activity and pregnancy course (fetal morphometric parameters, fetal heart rate, fetal growth, Doppler velocimetry) were collected. Gestational age, birth weight and APGAR score were also recorded.

Results: 29 pregnancies in 23 women affected by refractory JIA became pregnant during a 17 years follow up. All patients had a long lasting polyarticular disease (median duration of 23 years) not responsive to DMARDs, and became pregnant during biologic therapy. Patients were treated with Etanercept (11 patients), Golimumab (4 patients), Rituximab (3 patients), Adalimumab and Certolizumab (2 patients respectively) as monotherapy, and in most of the cases after multiple switches. One woman was treated with Etanercept during the first pregnancy and Adalimumab during her second pregnancy. Three patients decided for an elective termination and 3 experienced an early miscarriage; among 23 pregnancies resulting in live born infants, only 3 had premature births and 1 cleft palate. A pregnancy was complicated by gestosis, two by placental detachment. All the babies were followed up during the 17 years of observation and did not experience any major late complication. Eight patients were subjected to intra-articular infiltrations during pregnancy to switch off the disease, 18 patients resumed therapy shortly after childbirth and only 7 patients decided to breastfeed. Conclusion: Despite a large amount of studies demonstrating the safety of anti-TNF during pregnancy, data regarding the effects of biologics on pregnancy outcome in JIA are still lacking. The very low number of patients treated with traditional DMARDs achieving low disease activity underline the pivotal role of new biologic drugs in the management of aggressive long standing JIA; to improve the quality of life of these patients, including family planning. In our experience, no greater number of unexpected complications or side effects were observed in JIA patients during pregnancy compared to the other autoimmune diseases. Discontinuation of therapy has increased the risk of flare, requiring local therapy, confirming that EULAR recommendations for the use of biologics during pregnancy can be applied also in JIA.

REFERENCES:

Disclosure of Interests: None declared

FR10571

MEASUREMENT PERFORMANCE OF REDUCED VERSIONS OF MUSCLE STRENGTH TOOLS IN JUVENILE DERMATOMYOSITIS

Silvia Rosina1, Giulia Camilla Varieri2, Angela Pistoro1, Alessandro Consolaro1, Clarissa Pilkinson1, Susan Maillard1, Adele Civino1, Elena Tisitsi1, Jaime de Inocencio2, Manja Jelusic3, Jelena Vojvonic1, Graciela Espada1, Balahan Makay1, Maria Katksias1, Poliviene Pratsidou-Gertsis1, Dragana Lazarevic1, Anand Prahalad Rao14, Nicolino Ruperto1, Angelo Ravelli1.

Assessment of muscle strength is a fundamental component of the clinical evaluation of children with juvenile dermatomyositis (JDM). Regular measurement of muscle strength in daily care requires the availability of simple and quick muscle assessment tools.

Objectives: To investigate whether reduced versions of the MMT8 and CMAS are equally reliable as the original tools.

Methods: The following 4 reduced instruments were devised: 1) MMT4 (score 0-40), including 4 items of MMT8 (neck flexors, deltoid middle, gluteus maximus, and gluteus medius); 2) MMT6 (score 0-60), composed of the same items of MMT4 plus biceps brachii and quadriceps; 3) head tilt time of CMAS (0-120 seconds or 0-5 points); 4) sum of CMAS head tilt time in points and the 6 sit-ups maneuvers of CMAS (score 0-11). Validation was conducted according to OMERACT filter on 213 patients followed in standard clinical care at 13 international pediatric rheumatology centers and evaluated at baseline and after a median of 5.9 months.

Results: All reduced instruments revealed strong correlations (r > 0.7) with muscle activity VAS and total DAS, moderate correlations (r = 0.4-0.6) with pain VAS, patient’s overall wellbeing VAS, and CK. Correlations with skin DAS and fatigue VAS were low (r < 0.4). Cronbach’s alpha was excellent (0.92-0.95) for all reduced tools for which this property could be assessed. SRM was good-to-moderate (0.60-0.91) for all reduced instruments in patients judged as improved by the physician. All reduced tools discriminated between patients classified in different disease activity states by the physician (p < 0.0001), and between patients whose parents were satisfied or not satisfied with their children’s disease status (p < 0.0001). Overall, the metrcoolic performance of the reduced instruments was comparable to that of MMT8 and CMAS.

Conclusion: We found that reduced versions of the MMT8 and CMAS have good metrcoolic properties and perform similarly to the original tools in a population of patients followed in standard clinical care. Our results suggest that these simplified and shortened instruments could serve as surrogate for the complete measures in routine practice, particularly in a busy clinical setting.

REFERENCES:

Disclosure of Interests: Silvia Rosina: None declared, Giulia Camilla Varieri: None declared, Angela Pistoro: None declared, Alessandro Consolaro: None declared, Clarissa Pilkinson: None declared, Susan Maillard: None declared, Adele Civino: None declared, Elena Tisitsi: None declared, Jaime de Inocencio: None declared, Manja Jelusic: None declared, Jelena Vojvonic: None declared, Graciela Espada: None declared, Balahan Makay: None declared, Maria Katksias: None declared, Poliviene Pratsidou-Gertsis: None declared, Dragana Lazarevic: None declared, Anand Prahalad Rao: None declared, Nicolino Ruperto: Grant/research support from: The Gaslini Hospital, where NR works as full-time public employee, has received contributions (> 10.000 USD each) from the following industries in the last 3 years: BMS, Eli-Lilly, GlaxoSmithKline, F Hoffmann-La Roche, Novartis, Pfizer, Sobi. This funding has been reinvested for the research activities of the hospital in a fully independent manner, without any commitment with third parties., Consultant for: Received honoraria for consultancies or speaker bureaus (< 10.000 USD each) from the following pharmaceutical companies in the last 3 years: Ablynx, Abb-Vie, AstraZeneca-Medimmun, Biogen, Boehringer, Bristol-Myers Squibb, Eli-Lilly, EMD Serono, GlaxoSmithKline, Hoffmann-La Roche, Janssen, Merck, Novartis, Pfizer, R-Pharma, SanofiAventis, Sobi and Takeda., Speakers bureau: Received honoraria for consultancies or speaker bureaus (< 10.000 USD each) from the following pharmaceutical companies in the last 3 years: Ablynx, AbbVie, AstraZeneca-Medimmun, Biogen, Boehringer, Bristol-Myers Squibb, Eli-Lilly, EMD Serono, GlaxoSmithKline, Hoffmann-La Roche, Janssen, Merck, Novartis, Pfizer, R-Pharma, SanofiAventis, Sobi and Takeda., Angelo Ravelli: Grant/research support from: Angelivi, AbbVie, Bristol-Myers Squibb, Johnson & Johnson, Novartis, Pfizer, Reckitt Benkiser, and Roche, Consultant for: Angelivi, AbbVie, Bristol-Myers Squibb, Johnson & Johnson, Novartis, Pfizer, Reckitt Benkiser, and Roche, Speakers bureau: Angelivi, AbbVie, Bristol-Myers Squibb, Johnson & Johnson, Novartis, Pfizer, Reckitt Benkiser, and Roche, Angelo Ravelli: Grant/research support from: Angelivi, AbbVie, Bristol-Myers Squibb, Johnson & Johnson, Novartis, Pfizer, Reckitt Benkiser, and Roche.

FR10572

DISABILITY AND HEALTH-RELATED QUALITY OF LIFE OUTCOMES IN PATIENTS WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS TREATED WITH TOCILIZUMAB IN A PHASE 3 RANDOMIZED CONTROLLED TRIAL

Nicolino Ruperto1, Chen Chen1, Alberto Martini2, Graciela Espada1, Rik Jocos3, Jonathan Akkoula4, Jeffrey Chatow1, Maria Luz Gamir Gamis5, Yukiko Kinuma6, Christoph Rietschel7, Daniel Sri1, Elizbieta Smolewska1, Heinrike Schmelings4, Diane Brown1, Fabrizio De Benedetti1, Daniel J. Lovell2, Bin Huang1, Hermine Brunner1, Paediatric Rheumatology International Trials Organisation (PRINTO), Genoa, Italy;1 Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati Children’s Hospital Medical Center, Cincinnati, United States of America.

Background: Tocilizumab (TCZ) intravenous (IV) formulation was approved for the treatment of patients with systemic juvenile idiopathic arthritis (sJIA) based on the results of a large phase 3 clinical trial. Physical function, measured by the Childhood Health Assessment Questionnaire—Disability Index (CHAQ-DI), and health-related quality of life (HRQOL), measured by the Child Health Questionnaire (CHQ), were evaluated.

Objectives: To examine measures of disability and HRQOL in patients with sJIA treated with TCZ IV for up to 2 years in post hoc analysis of data from the phase 3 trial of TCZ.

Methods: Changes within 3 months of treatment initiation with TCZ (base-line) were compared between TCZ- and placebo (PBO)—treated patients using CHAQ-DI, pain global assessment (Pain-GA), physical global assessment, and patient global assessment (Pt-GA) using analysis of variance adjusted for treatment group. Changes in CHAQ-DI overall and domain scores and changes in CHQ domain and summary scores from baseline to 2 years were compared for patients treated with TCZ using the unpaired t test.

Results: Patients with sJIA experienced clinically relevant improvement in physical function (CHAQ-DI) and reduction of pain (Pain-GA). Mean (SD) CHAQ-DI scores for patients treated with PBO and TCZ were 1.7 (0.8) for both groups at baseline and 1.2 (1.0) and 0.9 (0.8), respectively, at week 12 (week 12 mean difference, −0.2; median [range] change from baseline to week 12 difference, −0.3 [−0.6 to 0.0]). These patients also had significantly improved CHQ socialization, behavior, mental health, and psychosocial summary scores after 3 months compared with those receiving PBO (Figure 1). Improvement in all CHAQ-DI domains over 2 years was observed with TCZ treatment (Figure 2); improvement rates in patient well-being (Pt-GA) were 87.7%. Similar improvements in physical function were observed in patients with polyarticular JIA in the phase 3 trial that led to approval of TCZ IV in these patients (not shown). There was also significant improvement (p<0.05) in most domains of HRQOL (CHQ domain scores) in patients with sJIA; of note, patients experienced improvements in pain improvement from baseline to week 104 for pain/discomfort (31.7 to 75.3), self-esteem (61.0 to 76.0), mental health (62.1 to 76.8), and social limitation-emotional (52.6 to 86.2).

Conclusion: Two years of TCZ treatment resulted in statistically significant and clinically relevant improvements in function and HRQOL in patients with sJIA.